Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN65,1165,142,13
Msft-0,17
Nokia3,29053,2965-1,02
IBM0,08
Mercedes-Benz Group AG73,8573,870,39
PFE-0,11
29.03.2024 1:04:00
Indexy online
AD Index online
select
AD Index online
 

  • 28.03.2024
Guerbet SA (GRBT.F, Frankfurt)
Závěr k 28.3.2024 Změna (%) Změna (EUR) Objem obchodů (EUR)
33,00 -3,37 -1,15 1 320
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 29.03.2024
Popis společnosti
Obecné informace
Název společnostiGuerbet SA
TickerGBT
Kmenové akcie:Ordinary Shares
RICGRBT.PA
ISINFR0000032526
Poslední známé roční výsledky31.12.2023
Poslední známé čtvrtletní výsledky31.12.2023
Počet zaměstnanců k 31.12.2022 2 839
Akcie v oběhu k 30.06.2023 12 622 444
MěnaEUR
Kontaktní informace
Ulice15 rue des Vanesses, Zone Paris Nord II
MěstoVILLEPINTE
PSČ93420
ZeměFrance
Kontatní osoba 
Funkce kontaktní osoby 
Telefon33 145 915 000
Fax33145915199

Business Summary: Guerbet SA is a France-based pharmaceutical group specialized in the manufacture and marketing of medical imaging contrast agents destined for diagnostic purposes. It produces medical imaging contrast products for x-ray imaging, magnetic resonance imaging (MRI), ultrasound imaging and for nuclear medicine. The contrast agents are used in the diagnosis of cardio-vascular, inflammatory and neuro-degenerative disorders. The Company’s portfolio of products comprises brands, such as Xenetix, Hexabrix, Optiray, Oxilan, Telebrix, Lipiodol, Dotarem, Endorem, Artirem, Lumirem, and Lipiodol, among others. Guerbet SA is also active in the fine chemicals industry through its Simafex subsidiary. The Company operates through its subsidiaries, including Simafex, Medex, SCI KALB, Guerbet LLC, Guerbet Asie Pacifique and Guerbet GmbH, among others.
Financial Summary: BRIEF: For the six months ended 30 June 2023, Guerbet SA revenues increased 2% to EUR378.6M. Net income applicable to common stockholders decreased 37% to EUR2.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income was offset by Staff-related costs increase of 12% to EUR135.5M (expense), External charges increase of 5% to EUR108.7M (expense).
Odvětvová klasifikace
TRBC2012Medical Imaging Systems
RBSS2004Pharmaceuticals - Generic & Specialty
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
NAICS2007Pharmaceutical Preparation Mfg
NAICS1997Pharmaceutical Preparation Manufacturing
SICPharmaceutical Preparations



  • Poslední aktualizace: 29.03.2024
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the Executive Committee, Chief Executive OfficerDavid Hale5401.01.2020
Chief Financial Officer, Senior Vice President - IT and Business Development and Licensing, Member of the Executive CommitteeJerome Estampes-01.01.2019
Senior Vice President - Compliance, General Counsel, Member of the Executive CommitteeCharlotte Bamiere-06.04.2022
Senior Vice President - Marketing - Diagnostic Imaging, Member of the Executive CommitteeValerie Brissart-
Senior Vice President - Human Resources, Member of the Executive CommitteeEva Ohlsson-11.03.202411.03.2024
Senior Vice President - Public Affairs and Corporate Communications, Member of the Executive CommitteeChristine Allard-11.03.202411.03.2024
Senior Vice President - Industrial Operations, EHS and Procurement, Member of the Executive CommitteeRaoul Bernhardt-01.01.2024
Senior Vice President - Development, Medical and Regulatory Affairs and Group Responsible Pharmacist, Member of the Executive CoPhilippe Bourrinet54
Senior Vice President - Research, Development, Innovation and AI, Member of the Executive CommitteeFrancois Nicolas-
Senior Vice President - Commercial Operations, Member of the Executive CommitteeDan Raffi-01.01.2024